• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CFH Gene Record

  • Summary
  • Interactions
  • Claims
  • CFH 3075 Druggable Genome

    Alternate Names:

    3075
    COMPLEMENT FACTOR H
    CFH
    AHUS1
    AMBP1
    ARMD4
    ARMS1
    CFHL3
    FH
    FHL1
    HF
    HF1
    HF2
    HUS
    134370
    4883
    ENSG00000000971
    OTTHUMG00000035607
    PA29261
    T71086
    BE0009053
    P08603

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (1 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME

    Publications:

    Habbig S et al., 2016, Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH., Am J Kidney Dis
    Medina FM et al., 2015, Pharmacogenetic Effect of Complement Factor H Gene Polymorphism in Response to the Initial Intravitreal Injection of Bevacizumab for Wet Age-Related Macular Degeneration., Ophthalmic Res
    Hautamäki A et al., 2013, Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration., Retina
    Kang HK et al., 2012, Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population., Korean J Ophthalmol
    Smailhodzic D et al., 2012, Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration., Ophthalmology
    Tian J et al., 2012, Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population., Pharmacogenomics
    Chang W et al., 2013, Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population., Mol Vis
    Lotery AJ et al., 2013, Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study., Ophthalmology
    Chen G et al., 2015, Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis., Sci Rep
    Park UC et al., 2014, Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration., Retina
    Hagstrom SA et al., 2013, Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT)., Ophthalmology
    Wang F et al., 2013, Immobilized metal affinity chromatography and human serum proteomics., J Chromatogr B Analyt Technol Biomed Life Sci
    Nan R et al., 2011, Zinc binding to the Tyr402 and His402 allotypes of complement factor H: possible implications for age-related macular degeneration., J Mol Biol
  • RANIBIZUMAB   CFH

    Interaction Score: 26.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26439641 23584701 23204795 22840423 22594510 23559864 24070809 26411831 23842101 23337555


    Sources:
    PharmGKB

  • ECULIZUMAB   CFH

    Interaction Score: 6.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26724167


    Sources:
    PharmGKB

  • BEVACIZUMAB   CFH

    Interaction Score: 2.54

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26439641 23584701 23204795 22840423 22594510 23559864 24070809 26411831 23842101 23337555


    Sources:
    PharmGKB

  • ZINC CHLORIDE   CFH

    Interaction Score: 0.2

    Interaction Types & Directionality:
    ligand

    Interaction Info:

    PMIDs:
    21396937


    Sources:
    DrugBank

  • COPPER   CFH

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23896426


    Sources:
    DrugBank

  • METHYLDOPA   CFH

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21396937


    Sources:
    DrugBank

  • Ensembl: ENSG00000000971

    • Version: 101_38

    Alternate Names:
    CFH Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • PharmGKB: CFH

    • Version: 18-August-2020

    Alternate Names:
    PA29261 PharmGKB ID

    Gene Info:

    Publications:
    Medina FM et al., 2015, Pharmacogenetic Effect of Complement Factor H Gene Polymorphism in Response to the Initial Intravitreal Injection of Bevacizumab for Wet Age-Related Macular Degeneration., Ophthalmic Res
    Hautamäki A et al., 2013, Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration., Retina
    Kang HK et al., 2012, Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population., Korean J Ophthalmol

  • DrugBank: BE0009053

    • Version: 5.1.7

    Alternate Names:
    CFH DrugBank Gene Name
    P08603 UniProt Accession
    3075 Entrez Gene Id

    Gene Info:

    Publications:
    Nan R et al., 2011, Zinc binding to the Tyr402 and His402 allotypes of complement factor H: possible implications for age-related macular degeneration., J Mol Biol
    Wang F et al., 2013, Immobilized metal affinity chromatography and human serum proteomics., J Chromatogr B Analyt Technol Biomed Life Sci

  • HingoraniCasas: ENSG00000000971

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000000971 Gene Symbol
    CFH Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TTD: Complement factor H

    • Version: 2020.06.01

    Alternate Names:
    CFH TTD Gene Abbreviation
    T71086 TTD Target ID

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21